Variation in uptake of sodium glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor analogues in adults with type 2 diabetes at high cardiovascular risk.

ABSTRACT:

Purpose

We quantified variation in the uptake of sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor analogues (GLP-1RA) across sociodemographic, behavioural and clinical characteristics of people with type 2 diabetes (T2D) at high cardiovascular risk.

Methods

We used the 45 and Up Study survey data (2018-2020) linked to dispensing and service claims for 10,171 people with T2D (56% male, median age of 72 years, median diabetes duration of 11 years). We calculated the prevalence of GLP-1RA and SGLT2i use within 1 year and used logistic regressions to assess associations with each participant characteristic.

Results

We found that 2270 (22.3%) people with T2D used SGLT2i and 679 (6.7%) used GLP-1RA. Use of these medicines was higher i

SUBMITTER: de Oliveira Costa J 

PROVIDER: S-EPMC12398476 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature